REGION: USA
INDUSTRY: Healthcare
TARGET AUDIENCE: Board Eligible/Certified Allergists or Immunologists in United States
BACKGROUND & KEY OBJECTIVES:
BACKGROUND: Hereditary Angioedema (HAE) is a rare but potentially life-threatening genetic disorder characterized by recurrent episodes of severe swelling, the management of HAE primarily involves allergists and HAE treaters who must stay informed about the latest treatment protocols, emerging therapies.
KEY OBJECTIVES:
The study was carried out to determine the key emphasis area of the company/specific department of the targeted audience, which included under developing drugs and approved marketed drugs, and so on. The survey questions were mainly focused on upcoming treatments in the market for HAE and in addition; to analysed multiple methods, they provided some dummy patient’s data in this survey to gather information about which upcoming product is useful for which patient.
METHODOLOGIES & APPROACH
Target Audience:
The study of aimed at Board Eligible/Certified Allergists/Immunologists and HAE treaters in the USA, including academic and clinical practice settings. Given the complexities of HAE, the interaction was intended to facilitate in-depth conversation and information transfer.
Approach:
To achieve the objectives, a 60-minute structured surveys were developed, blending expert presentations with interactive components. The methodologies employed included:
Comprehensive Webinar Series: A survey was conducted, each lasting 60 minutes, focusing on different aspects of HAE management from diagnosis to advanced treatment protocols. The survey was designed to provide a deep dive into each topic, ensuring that participants gained a thorough understanding.
Expert Panels: Each survey featured a panel of leading HAE specialists who presented real-time data. This not only provided practical insights but also allowed participants to see how theoretical knowledge is applied in clinical settings.
Conclusion:
This study successfully completed the educational needs of Board Eligible/Certified Allergists/Immunologists in the USA, providing them with the tools and knowledge necessary to enhance patient care with new treatments. The combination of expert insights, interactive learning, and comprehensive learning experience that not only informed but also empowered participants to make a tangible impact in their clinical practice.
